Key facts
- It has raised $37.5M; the latest was Accelerator/Incubator in Nov 2025.
- Notable investors include Bpifrance, Kima Ventures, La French Tech, XAnge, BNP Paribas Développement — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Synapse Global
- ·The full record, as it builds
Funding rounds
No funding rounds for Synapse Global are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Synapse Global
Developer of a medical intelligence platform designed to assist doctors in managing drug prescriptions. The company offers an interface for accessing reliable and current drug information to analyze treatments in real time and ensure the safety of drug therapies, enabling doctors and patients to access virtual medical assistance.
- Sector
- Healthcare
- HQ
- Bordeaux, France
- Founded
- 2017
- Employees
- 84
- Website
- synapse-medicine.com/
- Ownership
- Privately Held (backing)
Synapse Global doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Synapse Global shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Synapse Global in its N-PORT filings yet. We sweep new filings monthly.